Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Table1_Variation of leaf shape with tree size: a case study using Camptotheca acuminata Decne.xlsx by Ke He (331344)

“…However, DBH did not significantly affect the ratio W/L nor the leaf roundness index. …”

Spectral shift of fluorophore NHS-esters. by Hyunwoo Kim (690467)

“…After 5 min of illumination with a 561-nm excitation laser, the fluorescence signal in the 647-nm detection channel decreased, while the signal in the 561-nm detection channel significantly increased, indicating a spectral blue-shift of the emission spectrum. …”

Climate is more influential to vegetation green-up than factors that contribute to erosion following high-severity wildfire by Joseph Crockett (22077659)

“…In <a>highly erodible</a> scenarios, when accounting for growing season climate, coefficient of variation for year-of-fire precipitation, total precipitation, and soil erodibility decreased greenness in the fifth year. While the effects of year-of-fire factors related to erosion were significant, they were small, and the variability explained by growing season vapor pressure deficit and growing season precipitation were significantly greater.…”

The recruitment of Paf1C to the <i>frq</i> ORF is regulated by the WCC activity. by Mengmeng Zhou (9197699)

“…<p>(A) The enrichment of PAF-1 (Left) or RTF-1 (Right) at the <i>frq</i> ORF middle region significantly decreased in <i>wc-2</i>^<i>KO</i> strain at DD14. …”

Table 1_Stroke-associated pneumonia with low PaO2/FiO2 ratio in acute large vessel occlusion after endovascular therapy: risk factors and prognosis.docx by Kun Tang (75641)

“…A deterioration in SAP manifests itself in a decreased partial pressure oxygen (PaO₂)/fraction of inspired oxygen (FiO₂) ratio, indicating gas exchange dysfunction. …”

SNAP-25 (1-197) binds to syntaxin-1A, and the interaction is enhanced by Ser187 phosphorylation. by Dilara Koc (22431017)

“…Data are representative of 3 independent experiments, and results are presented as mean ± SD. *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001.…”

Table 1_GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.docx by Farah Ghobar (22480732)

“…Moreover, HbA1c levels were assessed in seven studies, where significant reductions in treatment groups were reported with a standardized mean difference of -6.95 (95% CI: [-14.24, 2.98], p-value= 0.06) for the overall effect size. …”

Supplementary Material for: DOT1L regulates cellular senescence during the progression from acute kidney injury to chronic kidney disease via the micro-222-5p/WNT9B signaling pathw... by figshare admin karger (2628495)

“…In the doxorubicin -induced HK-2 cell model, DOT1L inhibition markedly decreased cellular senescence and lowered mRNA and protein levels of senescence markers, while alleviating cell cycle arrest. …”